ABT logo

Abbott Laboratories (ABT) Accounts Receivable

Annual Accounts Receivable

$6.92 B
+$360.00 M+5.48%

December 1, 2024

Summary

Performance

1-Year Change

+5.48%

3-Year Change

+6.75%

5-Year Change

+27.65%

15-Year Change

+31.93%

ABT Accounts Receivable Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

97.73%
ABT annual accounts receivable is higher than 97.73% of companies in Healthcare sector

High & Low

All-time High

$7.68 B
ABT annual accounts receivable is currently -9.88% below its historical high of $7.68 billion

3-Year Low

$6.22 B
ABT annual accounts receivable is currently +11.37% above its 3-year low

Earnings dates

Last Annual Earnings Report Date

Dec 1, 2024
ABT previous annual earnings announcement was published on Dec 1, 2024

Next Annual Earnings Report Date

N/A
ABT next annual earnings announcement has not yet been scheduled

OtherABTbalance sheetmetrics:

Annual Accounts Payable

$4.20 B
ABT annual accounts payable is $4.20 billion

Annual Total Assets

$81.41 B
ABT annual total assets is $81.41 billion

Annual Total Liabilities

$33.51 B
ABT annual total liabilities is $33.51 billion

Annual Cash & Cash Equivalents

$7.62 B
ABT annual cash & cash equivalents is $7.62 billion

Quarterly Accounts Receivable

N/A

December 1, 2024

Summary

Performance

3-Month Change

-

1-Year Change

-

3-Year Change

-

5-Year Change

-

ABT Quarterly Accounts Receivable Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

High & Low

All-time High

$7.68 B
ABT quarterly accounts receivable is currently at an all-time high

3-Year Low

$6.02 B
ABT quarterly accounts receivable is currently at its 3-year low

Earnings dates

Last Quarterly Earnings Report Date

Dec 1, 2024
ABT previous earnings announcement was published on Dec 1, 2024

Next Quarterly Earnings Report Date

Apr 17, 2025
ABT next earnings announcement is scheduled for Apr 17, 2025

OtherABTbalance sheetmetrics:

Quarterly Accounts Payable

-
ABT quarterly accounts payable value is unknown

Quarterly Total Assets

$81.41 B
ABT quarterly total assets is $81.41 billion

Quarterly Total Liabilities

$33.51 B
ABT quarterly total liabilities is $33.51 billion

Quarterly Cash And Cash Equivalents

-
ABT quarterly cash and cash equivalents value is unknown

Accounts Receivable Formula

Accounts Receivable = Total Credit Sales − Amount Collected from Credit Sales

ABT Accounts Receivable Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterly
1 y1 year+5.5%-
3 y3 years+6.8%-
5 y5 years+27.6%-

ABT Accounts Receivable Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs low
3 y3-yearat high+11.4%
5 y5-yearat high+27.6%
alltimeall time-9.9%+456.5%

Abbott Laboratories Accounts Receivable History

DateAnnualQuarterly
Dec 2024
$6.92 B(+5.5%)
-
Sep 2024
-
$7.05 B(+2.9%)
Jun 2024
-
$6.85 B(+3.8%)
Mar 2024
-
$6.61 B(+0.6%)
Dec 2023
$6.57 B(+5.6%)
$6.57 B(+1.0%)
Sep 2023
-
$6.50 B(+5.3%)
Jun 2023
-
$6.17 B(+2.5%)
Mar 2023
-
$6.02 B(-3.2%)
Dec 2022
$6.22 B(-4.1%)
$6.22 B(-3.0%)
Sep 2022
-
$6.41 B(-11.0%)
Jun 2022
-
$7.20 B(+0.3%)
Mar 2022
-
$7.18 B(+10.7%)
Dec 2021
$6.49 B(+1.1%)
$6.49 B(+1.3%)
Sep 2021
-
$6.41 B(+4.8%)
Jun 2021
-
$6.11 B(+0.3%)
Mar 2021
-
$6.10 B(-5.0%)
Dec 2020
$6.41 B(+18.2%)
$6.41 B(+13.5%)
Sep 2020
-
$5.65 B(+9.9%)
Jun 2020
-
$5.14 B(-2.9%)
Mar 2020
-
$5.29 B(-2.5%)
Dec 2019
$5.42 B(+4.7%)
$5.42 B(-0.5%)
Sep 2019
-
$5.45 B(-1.8%)
Jun 2019
-
$5.55 B(+3.8%)
Mar 2019
-
$5.34 B(+3.1%)
Dec 2018
$5.18 B(-1.3%)
$5.18 B(-1.7%)
Sep 2018
-
$5.27 B(+1.5%)
Jun 2018
-
$5.19 B(-3.1%)
Mar 2018
-
$5.36 B(+2.0%)
Dec 2017
$5.25 B(+61.6%)
$5.25 B(+9.4%)
Sep 2017
-
$4.80 B(+3.6%)
Jun 2017
-
$4.63 B(+2.7%)
Mar 2017
-
$4.51 B(+38.9%)
Dec 2016
$3.25 B(-5.0%)
$3.25 B(-2.2%)
Sep 2016
-
$3.32 B(-6.9%)
Jun 2016
-
$3.57 B(+4.0%)
Mar 2016
-
$3.43 B(+0.4%)
Dec 2015
$3.42 B(-4.7%)
$3.42 B(-1.2%)
Sep 2015
-
$3.46 B(-2.6%)
Jun 2015
-
$3.55 B(+2.1%)
Mar 2015
-
$3.48 B(-2.9%)
Dec 2014
$3.59 B(-10.0%)
$3.59 B(-0.9%)
Sep 2014
-
$3.62 B(-10.8%)
Jun 2014
-
$4.06 B(+4.5%)
Mar 2014
-
$3.88 B(-2.6%)
Dec 2013
$3.99 B(-47.6%)
$3.99 B(+2.7%)
Sep 2013
-
$3.88 B(-1.4%)
Jun 2013
-
$3.94 B(+0.5%)
Mar 2013
-
$3.92 B(-48.5%)
Dec 2012
$7.61 B(-0.9%)
$7.61 B(+9.6%)
Sep 2012
-
$6.95 B(+2.7%)
Jun 2012
-
$6.77 B(-11.6%)
Mar 2012
-
$7.66 B(-0.3%)
Dec 2011
$7.68 B(+7.0%)
$7.68 B(+9.1%)
Sep 2011
-
$7.04 B(+0.1%)
Jun 2011
-
$7.04 B(-1.7%)
Mar 2011
-
$7.16 B(-0.3%)
Dec 2010
$7.18 B(+9.8%)
$7.18 B(+15.0%)
Sep 2010
-
$6.25 B(-1.4%)
Jun 2010
-
$6.34 B(-2.8%)
Mar 2010
-
$6.52 B(-0.3%)
Dec 2009
$6.54 B
$6.54 B(+19.5%)
Sep 2009
-
$5.47 B(+0.4%)
DateAnnualQuarterly
Jun 2009
-
$5.45 B(+4.3%)
Mar 2009
-
$5.23 B(+4.7%)
Sep 2008
-
$4.99 B(-3.8%)
Jun 2008
-
$5.19 B(+3.8%)
Mar 2008
-
$5.00 B(+1.0%)
Dec 2007
$4.95 B(+16.9%)
$4.95 B(+17.5%)
Sep 2007
-
$4.21 B(+24.0%)
Jun 2007
-
$3.40 B(+3.6%)
Mar 2007
-
$3.28 B(-22.5%)
Dec 2006
$4.23 B(+18.3%)
$4.23 B(+18.3%)
Sep 2006
-
$3.58 B(-2.6%)
Jun 2006
-
$3.67 B(+9.9%)
Mar 2006
-
$3.34 B(-6.5%)
Dec 2005
$3.58 B(-3.2%)
$3.58 B(+11.7%)
Sep 2005
-
$3.20 B(-4.3%)
Jun 2005
-
$3.35 B(-5.4%)
Mar 2005
-
$3.54 B(-4.3%)
Dec 2004
$3.70 B(+11.6%)
$3.70 B(+25.5%)
Sep 2004
-
$2.95 B(+3.0%)
Jun 2004
-
$2.86 B(-10.6%)
Mar 2004
-
$3.20 B(-3.4%)
Dec 2003
$3.31 B(+13.2%)
$3.31 B(+15.0%)
Sep 2003
-
$2.88 B(+1.7%)
Jun 2003
-
$2.83 B(+2.6%)
Mar 2003
-
$2.76 B(-5.6%)
Dec 2002
$2.93 B(+4.1%)
$2.93 B(+2.2%)
Sep 2002
-
$2.87 B(+1.4%)
Jun 2002
-
$2.83 B(+6.9%)
Mar 2002
-
$2.64 B(-6.0%)
Dec 2001
$2.81 B(+29.1%)
$2.81 B(+4.6%)
Sep 2001
-
$2.69 B(+7.9%)
Jun 2001
-
$2.49 B(-2.5%)
Mar 2001
-
$2.55 B(+17.2%)
Dec 2000
$2.18 B(+6.0%)
$2.18 B(+7.4%)
Sep 2000
-
$2.03 B(-0.5%)
Jun 2000
-
$2.04 B(+5.1%)
Mar 2000
-
$1.94 B(-5.6%)
Dec 1999
$2.06 B(+5.1%)
$2.06 B(+9.2%)
Sep 1999
-
$1.88 B(-1.4%)
Jun 1999
-
$1.91 B(-3.7%)
Mar 1999
-
$1.98 B(+1.4%)
Dec 1998
$1.96 B(+9.7%)
$1.96 B(+12.9%)
Sep 1998
-
$1.73 B(-1.5%)
Jun 1998
-
$1.76 B(+3.4%)
Mar 1998
-
$1.70 B(-4.5%)
Dec 1997
$1.78 B(+4.3%)
$1.78 B(+4.8%)
Sep 1997
-
$1.70 B(-1.7%)
Jun 1997
-
$1.73 B(-0.1%)
Mar 1997
-
$1.73 B(+1.3%)
Dec 1996
$1.71 B(+9.3%)
$1.71 B(+10.3%)
Sep 1996
-
$1.55 B(-5.7%)
Jun 1996
-
$1.64 B(+5.2%)
Mar 1996
-
$1.56 B(-0.0%)
Dec 1995
$1.56 B(+6.4%)
$1.56 B(+6.3%)
Sep 1995
-
$1.47 B(-3.2%)
Jun 1995
-
$1.52 B(-1.9%)
Mar 1995
-
$1.55 B(+5.5%)
Dec 1994
$1.47 B(+9.9%)
$1.47 B(-0.2%)
Sep 1994
-
$1.47 B(+2.7%)
Jun 1994
-
$1.43 B(+6.2%)
Mar 1994
-
$1.35 B(+1.1%)
Dec 1993
$1.34 B(+7.4%)
$1.34 B(+7.4%)
Dec 1992
$1.24 B
$1.24 B

FAQ

  • What is Abbott Laboratories annual accounts receivable?
  • What is the all time high annual accounts receivable for Abbott Laboratories?
  • What is Abbott Laboratories annual accounts receivable year-on-year change?
  • What is the all time high quarterly accounts receivable for Abbott Laboratories?

What is Abbott Laboratories annual accounts receivable?

The current annual accounts receivable of ABT is $6.92 B

What is the all time high annual accounts receivable for Abbott Laboratories?

Abbott Laboratories all-time high annual accounts receivable is $7.68 B

What is Abbott Laboratories annual accounts receivable year-on-year change?

Over the past year, ABT annual accounts receivable has changed by +$360.00 M (+5.48%)

What is the all time high quarterly accounts receivable for Abbott Laboratories?

Abbott Laboratories all-time high quarterly accounts receivable is $7.68 B